Project Grant R01CA294824
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$539K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
The National Cancer Institute awarded a $704,563 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Beckman Research Institute of the City of Hope to develop quantitative MRI (qMRI) tools and automated prostate cancer tumor segmentation methods. The project aims to improve the identification of clinically significant prostate tumors in order to enhance radiation therapy targeting and improve patient outcomes, without increasing radiation toxicity.
Key products and...
This $607,131 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) is funding a research project to develop an MRI-guided robotic system for minimally invasive, personalized prostate cancer surgery. The overarching goal is to replace invasive radical prostatectomy with targeted, image-guided focal resection of prostate tumors.
The key products/services being developed include: 1) Fast intraoperative low-field MRI imaging to...
The National Cancer Institute (NCI) awarded a $692,072 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The University of Texas Southwestern Medical Center. The grant, effective September 19, 2024 through August 31, 2029, aims to develop a multimodal theranostic platform targeting prostate cancer (PC).
The proposed theranostic agents leverage Prostate-Specific Membrane Antigen (PSMA) targeting to enable concurrent positron emission tomography/computed...
The National Cancer Institute (NCI) awarded a $680,433 project grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at improving prognostic estimation and understanding of prostate cancer biology and heterogeneity. The 5-year project seeks to:
Evaluate the competitive and additive relationships between standard-of-care genomic expression and pathology artificial...
This R01 project grant, awarded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a fast and reproducible magnetic resonance fingerprinting (MRF) technique to quantitatively characterize prostate tissue and improve the detection of clinically significant prostate cancer. The $598,046 award to Case Western Reserve University, effective July 1, 2024 through June 30, 2029, aims to create novel MRF methods that...
The National Cancer Institute (NCI) awarded a $327,496 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Missouri System to design and develop implementation interventions aimed at improving the quality of active surveillance for men with favorable-risk prostate cancer. The key objectives are to: 1) assess the relative importance of implementation determinants, 2) design tailored interventions to support quality surveillance in urology...
The National Cancer Institute awarded a $627,474 Project Grant under its Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Dana-Farber Cancer Institute in Boston, Massachusetts. The grant will fund a 5-year research project titled "Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making." The project aims to utilize innovative...
The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...
This $644,622 Project Grant was awarded by the National Cancer Institute (NCI), under the Federal Grant Program titled "Cancer Treatment Research" (CFDA 93.395), to Regents of the University of Michigan on September 17, 2024.
The grant aims to develop tools and predictive models that will enable dosimetry-guided, personalized delivery of Radioligand Therapy (RLT) for metastatic castrate-resistant prostate cancer (mCRPC). Key objectives include: 1) Developing a novel method for bone...
The Department of the Army Medical Command awarded a $871,390 project grant to H. Lee Moffitt Cancer Center And Research Institute Lifetime Cancer Screening Center, Inc. to support data science research improving treatment planning for advanced prostate cancer patients receiving radiotherapy. Funded through the Military Medical Research and Development program, this three-year award beginning June 1, 2022 seeks to transform patient care for service members and the public through innovative...